Ipsen's 2012 financials beat own projections

30 January 2013

French drugmaker Ipsen (Euronext: IPN) posted financial results for 2012, showing that group sales rose 5.1% to 1.22 billion euros ($1.64 billion), despite a 4.3% decline to 518.5 million euros in its largest geographical region, Major Western European countries. Specialty care product turnover rose 13.6% to 862.5 million euros, while primary care sales slumped 11.9% to 324.6 million euros, negatively impacted by performance in France, down 29.7%. However, the company said that sales for the year were above the firm’s objectives.

In the fourth quarter 2012, group drug sales were stable year-on-year, driven by specialty care up 8.6%, fully offset by a decline of French primary care sales, down 17.3% year-on-year. Consolidated group sales reached 294.9 million euros, down 0.3% year-on year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Pharmaceutical